SEC Filing Summary: GSK Plc (Form 6-K)
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated May 13, 2025, reports a transaction in the company's own shares. The filing discloses a share repurchase executed on May 12, 2025, pursuant to a non-discretionary agreement with Citigroup Global Markets Limited entered into on February 24, 2025.
Key Financial Metrics and Transaction Details
- Shares Purchased: 812,010 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,331.00 GBp; highest price paid was 1,404.50 GBp.
- Average Price: Volume-weighted average price paid was 1,372.58 GBp.
- Trading Venue: All transactions occurred on the London Stock Exchange (XLON).
- Treasury Shares: Following this purchase, GSK holds 209,740,442 ordinary shares in treasury.
- Shares in Issue: 4,105,515,946 ordinary shares (excluding treasury shares).
- Total Voting Rights: 4,105,515,946.
Material Changes and Program Progress
This transaction is part of GSK's existing buyback programme. Since the programme's inception on February 24, 2025, the company has purchased an aggregate of 40,670,139 ordinary shares. The filing does not provide comparative financial performance data (revenue, profit, cash flow) as it is a disclosure of a specific capital transaction rather than a periodic financial report.
Outlook, Risks, and Management Commentary
The filing includes a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in the company's Annual Report on Form 20-F for 2024 and its Q1 Results for 2025. No new guidance or specific management commentary regarding operational outlook is provided in this document.
Investor Verification Checklist
- Verify the total number of shares purchased under the buyback programme since February 24, 2025 (stated as 40,670,139).
- Confirm the current number of treasury shares held (209,740,442) against the total authorized buyback limit, if publicly disclosed elsewhere.
- Review the "Risk Factors" section of the 2024 Form 20-F and Q1 2025 results for context on the company's financial health and buyback rationale.
- Check the denominator for disclosure thresholds under FCA rules, which is confirmed as 4,105,515,946 voting rights.